Life sciences · Preprint
arXiv · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
While a centralized approach involving patient consent to collect and analyze data centrally would theoretically offer the best data quality and predictive performance, it is not always feasible in practice. Federated Learning (FL) architectures have shown to be a very promising approach to use and access distributed disease related resources within the GDPR boundaries. In a previous case report, we described the preconditions at the participating sites and necessary administrative and process related steps to prepare data, people and infrastructure for improving subtype identification and assessing treatment options in pancreatic cancer. We update this report sharing our experience in tackling the challenges and show preliminary results of the actual federated learning AI pipelines. At the participating sites, we have to identify and annotate the data being accessible after extraction and transformation in a local FL hub - in our case a centrally developed and distributively deployed Docker container. This container comprises the FL scripts generating local models. We apply a newly developed FL algorithm considering all local features, including partial overlapping features specific to the local sites. Theoretically, an annotation in a cancer setting should succeed using the German oncology core data set (oBDS), which is already utilized for mandatory reporting to cancer registries, and can be sustained in the FL setting. The FL algorithms deal robustly with partially overlapping features as we showed with public data sets. Major roadblocks including straightening operational concepts for the infrastructures, ethics approval for such novel architectures and support for every site have been addressed. However, scaling up this approach in the future faces hurdles; while including broader multi-modal data sets should be feasible, large-scale deployment to more sites remains challenging.